吸入性糖皮質(zhì)激素預防早產(chǎn)兒慢性肺疾病有效性和安全性的meta分析
[Abstract]:Objective to evaluate the efficacy and safety of inhaled glucocorticoid in the prevention of (CLD) in premature infants with chronic lung disease. Methods both Pub Med,EMBASE,CENTRAL,the ISI Web of Knowledge Databases,CBM,CNKI and VIP,Wan Fang Data, were searched by computer until October 2016. All randomized controlled trials (RCT),) to study the efficacy and safety of inhaled glucocorticoid in preventing and treating CLD in premature infants were collected and RCT screening was performed. Data extraction and quality evaluation, meta analysis using Rev Man 5.3 software. Results A total of 12 RCT,2 cases were included in this study. Compared with the control group, there was no significant difference in the incidence of CLD in the 28 day inhaled glucocorticoid group, the inhaled budesonide subgroup, beclomethasone subgroup and fluticasone subgroup (P0. 05). Compared with the control group, The incidence of corticosteroid inhalation (RR=0.70,95%CI:0.61~0.80), nebulized inhaled subgroup (RR=0.74,95%CI:0.63~0.87), intratracheal administration subgroup (RR=0.57,95%CI:0.43~0.76), budesonide subgroup (RR=0.67;95%CI:0.57~0.78) and fluticasone subgroup (RR=0.58,95%CI:0.36~0.94), CLD) in 36 weeks of corrected gestational age group were significantly different, whereas the incidence of CLD in beclomethasone group was significantly higher than that in beclomethasone group (P < 0. 05). There was no significant difference between the incidence rate and the control group (P < 0.90), there was no significant difference in the overall mortality rate (P < 0.55), the nebulization subgroup, the intratracheal administration subgroup and the budesonide subgroup were not significantly different from those in the control group. There was no significant difference in mortality between betamethasone subgroup and fluticasone subgroup (P 0.05). Conclusion prophylactic use of inhaled glucocorticoids can effectively reduce the incidence of CLD in premature infants, but has no effect on the mortality, and has no significant correlation with the administration mode and type of administration. At the same time, 36 weeks of corrected gestational age is recommended as the observation point of outcome, but the number of related studies is limited and there is no long-term follow-up results. Therefore, the role of inhaled glucocorticoids and long-term complications still need a large number of clinical studies to evaluate. Clinical caution is recommended.
【作者單位】: 西南醫(yī)科大學附屬醫(yī)院新生兒科;
【分類號】:R722.6
【相似文獻】
相關期刊論文 前10條
1 毛一馨;早期使用地塞米松——嘗試防止慢性肺疾病[J];國外醫(yī)學.婦產(chǎn)科學分冊;2001年06期
2 富建華,薛辛東;慢性肺疾病早產(chǎn)鼠肺組織轉化生長因子β_1基因及蛋白表達的動態(tài)變化(英文)[J];中國當代兒科雜志;2005年03期
3 禹定樂;劉恩梅;;病毒感染與常見兒童慢性肺疾病相關性研究進展[J];兒科藥學雜志;2012年07期
4 富建華,薛辛東;慢性肺疾病早產(chǎn)鼠轉化生長因子β_1基因和蛋白動態(tài)表達及其對肺發(fā)育的抑制作用[J];中華兒科雜志;2005年06期
5 尚云曉;;慢性肺疾病及其診斷思路[J];中國實用兒科雜志;2007年04期
6 王穎;支氣管肺發(fā)育不良(新生兒慢性肺疾病)的診斷與治療[J];實用醫(yī)學雜志;2005年17期
7 張謙慎;常立文;容志惠;;早產(chǎn)兒慢性肺疾病支氣管肺泡灌洗液中細胞外基質(zhì)的變化[J];中國實用兒科雜志;2006年09期
8 全裕鳳;鄭明慈;;早產(chǎn)兒慢性肺疾病的防治現(xiàn)狀及展望[J];華夏醫(yī)學;2009年05期
9 羅英;唐麗君;黃為民;;慢性肺疾病患兒外周血細胞因子的改變[J];中國當代兒科雜志;2010年11期
10 王愛武;;經(jīng)鼻持續(xù)氣道正壓通氣在早產(chǎn)兒呼吸窘迫綜合征中應用探討[J];中國臨床新醫(yī)學;2013年05期
相關會議論文 前2條
1 常立文;李文斌;陳曄;張煉;盧紅艷;;新生兒慢性肺疾病的診治探討(附60例病例分析)[A];中華醫(yī)學會第十四次全國兒科學術會議論文匯編[C];2006年
2 高喜容;吳運芹;李磊;黃玫;劉暉;;早產(chǎn)兒慢性肺疾病臨床分析[A];中華醫(yī)學會第十四次全國兒科學術會議論文匯編[C];2006年
相關碩士學位論文 前3條
1 張杰;高氧致早產(chǎn)鼠慢性肺疾病中血小板源性生長因子及受體變化的研究[D];中國醫(yī)科大學;2004年
2 袁杰;高氧致慢性肺疾病早產(chǎn)鼠肺組織Foxa_2的表達及意義[D];瀘州醫(yī)學院;2010年
3 高英;高氧致慢性肺疾病早產(chǎn)鼠肺組織CDK4、P21的表達及意義[D];中國醫(yī)科大學;2006年
,本文編號:2284072
本文鏈接:http://sikaile.net/yixuelunwen/eklw/2284072.html